Share Market Newspaper

Rheumatoid Arthritis Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | ICMBIO, IGM Biosciences, Iltoo Pharma, Imcyse, Immutep, Lynk Pharma, Novartis, NovImmune, Nurix, Sorrento

 Breaking News
  • No posts were found

Rheumatoid Arthritis Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | ICMBIO, IGM Biosciences, Iltoo Pharma, Imcyse, Immutep, Lynk Pharma, Novartis, NovImmune, Nurix, Sorrento

November 08
18:42 2023
Rheumatoid Arthritis Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | ICMBIO, IGM Biosciences, Iltoo Pharma, Imcyse, Immutep, Lynk Pharma, Novartis, NovImmune, Nurix, Sorrento
Delveinsight Business Research LLP
The Rheumatoid Arthritis Market size in the 7MM was USD 27 billion in 2021 and it is projected to grow during the forecast period (2023-2032). The Rheumatoid Arthritis Market is anticipated to evolve immensely in the coming years owing to the rising prevalent population, extensive research and development activities of pharmaceutical companies, the rise in healthcare spending across the world, and the expected launch of new therapies in the market.

DelveInsight’s “Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Rheumatoid Arthritis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Rheumatoid Arthritis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Rheumatoid Arthritis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Rheumatoid Arthritis: An Overview

Rheumatoid arthritis (RA) is an autoimmune systemic inflammatory disorder that mainly affects the diarthrodial joint. It is the most common form of inflammatory arthritis and is characterized by inflammatory pathways that lead to the proliferation of synovial cells in joints. Overproduction of pro-inflammatory cytokines, including tumor necrosis factor (TNF) and interleukin-6, drives the destructive process. Subsequent pannus formation may lead to underlying cartilage destruction and bony erosions.

RA can affect multiple organs, such as the cardiovascular or respiratory systems; therefore, it is called a systemic disease. Rheumatoid arthritis most commonly affects the joints of the hands, feet, wrists, elbows, knees, and ankles. There is generally a bilateral/symmetrical pattern of disease progression (e.g., both hands or both knees are affected).

Rheumatoid Arthritis Market Key Facts

  • The total market size of Rheumatoid Arthritis in the United States is expected to increase with a CAGR of 2.8% during the study period (2019–2032).

  • Among EU4 countries, Germany has the maximum revenue share in 2021, while Spain has the lowest market share.

  • The Rheumatoid Arthritis market size in Japan was found to be USD 3 billion in 2021.

  • The total prevalent population of Rheumatoid Arthritis in the 7MM comprised 4,724,978 cases in 2021 and is projected to increase during the forecast period.

  • The total diagnosed prevalent cases of Rheumatoid Arthritis in the US were 1,256,779 in 2021

  • The United States contributed to the largest diagnosed cases of Rheumatoid Arthritis, accounting for ~ 30% of the 7MM in 2021.

  • Among EU4 countries, Germany accounted for the highest number of Rheumatoid Arthritis cases, whereas France accounted for the lowest number of cases in 2021.

Rheumatoid Arthritis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Rheumatoid Arthritis pipeline therapies. It also thoroughly assesses the Rheumatoid Arthritis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Rheumatoid Arthritis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Rheumatoid Arthritis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Rheumatoid Arthritis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Rheumatoid Arthritis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Rheumatoid Arthritis Epidemiology, Segmented as –

  • Prevalent cases of Rheumatoid Arthritis

  • Age-specific cases of Rheumatoid Arthritis

  • Diagnosed and Treatable Cases of Rheumatoid Arthritis

  • Gender-specific cases of Rheumatoid Arthritis

Rheumatoid Arthritis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Rheumatoid Arthritis market or expected to be launched during the study period. The analysis covers the Rheumatoid Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Rheumatoid Arthritis drugs based on their sale and market share.

The report also covers the Rheumatoid Arthritis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Rheumatoid Arthritis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Rheumatoid Arthritis Market Will Evolve and Grow by 2032 @

Rheumatoid Arthritis Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Rheumatoid Arthritis. Currently, RHEACELL is leading the therapeutics market with its Rheumatoid Arthritis drug candidates in the most advanced stage of clinical development.

Rheumatoid Arthritis Companies Actively Working in the Therapeutics Market Include

I-Mab Biopharma Co. Ltd., ICMBIO, IGM Biosciences, Inc., Iltoo Pharma, Imcyse, Immutep Limited, Innocare Pharma Australia Pty Ltd, Intrinsic Medicine, Janssen Research & Development, Jiangsu Hengrui Medicine, Jubilant Therapeutics, Kangstem Biotech, Kiniksa Pharmaceuticals, Ltd., KLUS Pharma, Kolon TissueGene, Kymera Therapeutics, Landos Biopharma, Lynk Pharmaceuticals, Lysatpharma GmbH, Mesoblast, MetrioPharm, Minghui Pharmaceutical Pty Ltd, Modern Biosciences, MyMD Pharmaceuticals, Neutrolis Therapeutics, Novartis, NovImmune, Nurix, Oryn Therapeutics, Pfizer, Philogen, PrecisionLife, R-Pharm, Regen BioPharma Inc., RemeGen, Revolo Biotherapeutics, RheumaGen, ROS Therapeutics, Rottapharm Biotech, SciRhom, Servatus Biopharmaceuticals, SFA Therapeutics, Silo Pharma, SinoMab Bioscience Ltd, Sonoma Biotherapeutics, Sorrento Therapeutics, Synact Pharma, Synermore Biologics Co., Ltd., Taiho Pharmaceutical, Teijin Pharma, Tiziana Life Sciences, Vaccinex Inc., Vyne Therapeutics, Worg Pharmaceuticals, Yuyu Pharma, Inc., and others.

Emerging and Marketed Rheumatoid Arthritis Therapies Covered in the Report Include:

ABBV-3373: Abbvie, ABX464: Abivax, AP1189: Synact Pharma, Dazodalibep: Horizon Therapeutics, Dekavil: Philogen, ENBREL (etanercept): Immunex/Amgen, HUMIRheumatoid Arthritis (adalimumab): AbbVie, OLUMIANT (barticinib): Eli Lilly/Incyte Corporation, Otilimab (GSK3196165/MOR103): GlaxoSmithKline, PF-06650833: Pfizer, Rabeximod (Rob 803): Cyxone, RC18: RemeGen, RINVOQ (upadacitinib): AbbVie, SHR0302: Jiangsu Hengrui Medicine, SM03: SinoMab, Zalunfiban: CeleCor Therapeutics, Zunsemetinib (ATI-450): Aclaris Therapeutics, and many others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Rheumatoid Arthritis Competitive Intelligence Analysis

4. Rheumatoid Arthritis Market Overview at a Glance

5. Rheumatoid Arthritis Disease Background and Overview

6. Rheumatoid Arthritis Patient Journey

7. Rheumatoid Arthritis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Rheumatoid Arthritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Rheumatoid Arthritis Unmet Needs

10. Key Endpoints of Rheumatoid Arthritis Treatment

11. Rheumatoid Arthritis Marketed Therapies

12. Rheumatoid Arthritis Emerging Drugs and Latest Therapeutic Advances

13. Rheumatoid Arthritis Seven Major Market Analysis

14. Attribute Analysis

15. Rheumatoid Arthritis Market Outlook (In US, EU5, and Japan)

16. Rheumatoid Arthritis Companies Active in the Market

17. Rheumatoid Arthritis Access and Reimbursement Overview

18. KOL Views on the Rheumatoid Arthritis Market

19. Rheumatoid Arthritis Market Drivers

20. Rheumatoid Arthritis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Hypertrophic Scar Market

“Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hypertrophic Scar market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hypertrophic Scar market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States